Prosecution Insights
Prosecution Insights
8 pending office actions • 5 art units • 6 examiners • 0 of 8 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (38%) |
| §103 only | 3 (38%) |
| §102 only | 1 (12%) |
| Multi-statute (no §101) | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BLUMEL, BENJAMIN P | 2 | 70.7% | +30.6% |
| SPENCER, ANDREA LYNNE MORRIS | 2 | 28.6% | +83.3% |
| MATALKAH, FATIMAH KHALAF | 1 | 55.3% | +28.5% |
| LI, BAO Q | 1 | 75.5% | +26.4% |
| SALVOZA, M FRANCO G | 1 | 68.9% | +29.2% |
| GU, QINHUA | 1 | 77.3% | +27.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18016344 | MULTIVALENT BETA-CORONAVIRUS VACCINES, THEIR DESIGNS AND USES | BLUMEL, BENJAMIN P | — |
| 17998607 | ENGINEERING CORONAVIRUS SPIKE PROTEINS AS VACCINE ANTIGENS, THEIR DESIGN AND USES | BLUMEL, BENJAMIN P | — |
| 17996727 | ENGINEERING BROADLY REACTIVE CORONAVIRUS VACCINES AND RELATED DESIGNS AND USES | SALVOZA, M FRANCO G | — |
| 17995128 | ENHANCEMENT OF THE PRODUCTION OF ADENOVIRUS-BASED GENE TRANSFER VECTORS | SPENCER, ANDREA LYNNE MORRIS | — |
| 17758077 | CULTURE SYSTEMS FOR THE EFFICIENT PRODUCTION OF GENE TRANSFER VECTORS | SPENCER, ANDREA LYNNE MORRIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18252790 | DESIGN OF OPTIMIZED UNIVERSAL INFLUENZA VACCINES, THEIR DESIGNS AND USES | LI, BAO Q | 84d overdue |
| 18264104 | GENE THERAPY FOR RETINAL DISEASES | MATALKAH, FATIMAH KHALAF | — |
| 18016344 | MULTIVALENT BETA-CORONAVIRUS VACCINES, THEIR DESIGNS AND USES | BLUMEL, BENJAMIN P | — |
| 17998607 | ENGINEERING CORONAVIRUS SPIKE PROTEINS AS VACCINE ANTIGENS, THEIR DESIGN AND USES | BLUMEL, BENJAMIN P | — |
| 17996727 | ENGINEERING BROADLY REACTIVE CORONAVIRUS VACCINES AND RELATED DESIGNS AND USES | SALVOZA, M FRANCO G | — |
| 17995128 | ENHANCEMENT OF THE PRODUCTION OF ADENOVIRUS-BASED GENE TRANSFER VECTORS | SPENCER, ANDREA LYNNE MORRIS | — |
| 17907571 | MAINTAINING DNA FRAGMENTS IN EUKARYOTIC CELLS, APPROACHES AND USES | GU, QINHUA | — |
| 17758077 | CULTURE SYSTEMS FOR THE EFFICIENT PRODUCTION OF GENE TRANSFER VECTORS | SPENCER, ANDREA LYNNE MORRIS | — |
| Art Unit | Apps |
|---|---|
| 1671 | 3 |
| 1631 | 2 |
| 1638 | 1 |
| 1672 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18264104 | GENE THERAPY FOR RETINAL DISEASES | MATALKAH, FATIMAH KHALAF | 1638 | §103 | Non-Final OA | — | Pending | Aug 03, 2023 |
| 18252790 | DESIGN OF OPTIMIZED UNIVERSAL INFLUENZA VACCINES, THEIR DESIGNS AND USES | LI, BAO Q | 1671 | §102 | Final Rejection | 84d overdue | Pending | May 12, 2023 |
| 18016344 | MULTIVALENT BETA-CORONAVIRUS VACCINES, THEIR DESIGNS AND USES | BLUMEL, BENJAMIN P | 1671 | §101§102§112Other | Non-Final OA | — | Pending | Jan 15, 2023 |
| 17998607 | ENGINEERING CORONAVIRUS SPIKE PROTEINS AS VACCINE ANTIGENS, THEIR DESIGN AND USES | BLUMEL, BENJAMIN P | 1671 | §101§102§103§112Other | Non-Final OA | — | Pending | Nov 11, 2022 |
| 17996727 | ENGINEERING BROADLY REACTIVE CORONAVIRUS VACCINES AND RELATED DESIGNS AND USES | SALVOZA, M FRANCO G | 1672 | §101§102§103§112Other | Final Rejection | — | Pending | Oct 20, 2022 |
| 17995128 | ENHANCEMENT OF THE PRODUCTION OF ADENOVIRUS-BASED GENE TRANSFER VECTORS | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103 | Final Rejection | — | Pending | Sep 30, 2022 |
| 17907571 | MAINTAINING DNA FRAGMENTS IN EUKARYOTIC CELLS, APPROACHES AND USES | GU, QINHUA | 1633 | §103 | Final Rejection | — | Pending | Sep 28, 2022 |
| 17758077 | CULTURE SYSTEMS FOR THE EFFICIENT PRODUCTION OF GENE TRANSFER VECTORS | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103§112 | Final Rejection | — | Pending | Jun 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial